Physician profile

John E Cebe

Cardiovascular Disease · Greenville, SC

NPI 1972595536

$1,624.82

in general payments reported to CMS, 2019-2025

20 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $361.44 2019-2022
Amgen INC. $213.84 2019-2022
Gilead Sciences, INC. $154.40 2019
Biosense Webster, INC. $121.12 2021
Edwards Lifesciences Corporation $111.08 2019
Sanofi-Aventis U.S. LLC $94.15 2019
Amarin Pharma, INC. $93.42 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $88.83 2019-2022
Astrazeneca Pharmaceuticals LP $80.85 2019-2022
Novartis Pharmaceuticals Corporation $70.93 2019-2022
Bayer Healthcare Pharmaceuticals INC. $59.53 2021-2022
Pfizer INC. $45.29 2020-2022
Merck Sharp & Dohme LLC $23.46 2021
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $23.07 2019
Abbott Laboratories $22.29 2021
Show all 20 companies
CompanyGeneral paymentsYearsTop products
Cook Medical LLC $14.67 2019
E.R. Squibb & Sons, L.L.C. $12.35 2019
Medtronic Vascular, INC. $11.54 2019
Regeneron Healthcare Solutions, INC. $11.44 2020
Boston Scientific Corporation $11.12 2020

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John E Cebe

$1,624.82

in general payments reported 2019-2025

Years
2019-2022
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/225090/john-e-cebe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.